
    
      To determine the MTD and any DLT of MM 111 when administered in combination with either 1)
      cisplatin, capecitabine, and trastuzumab; 2) lapatinib +/- trastuzumab; 3) paclitaxel and
      trastuzumab 4) lapatinib, paclitaxel and trastuzumab or 5) docetaxel and trastuzumab in
      patients with human epidermal growth factor receptor (HER2+) solid tumors
    
  